menu

NEWS

Angstrom Bio Raises $3M in Private Financing

Jun 16, 2021 | staff reporter NEW YORK — Angstrom Bio said on Wednesday that it has secured a $3 million investment that it will use to launch a nanopore sequencing-based test that simultaneously detects SARS-CoV-2 infection and identifies variants of the virus and to develop a multiplexed panel for respiratory pathogens. The investment was led by GreyBird Ventures. In connection with the financing, GreyBird cofounders Scott Gazelle and Tom Miller have joined Angstrom’s board of directors. Angstrom was founded in 2019 to develop antibody therapeutics but pivoted to SARS-CoV-2 diagnostics at the start of the pandemic. The Austin, Texas-based company uses a technology, dubbed...

READ MORE
Germany’s GNA Biosolutions Commercializing Rapid MDx Instrument, SARS-CoV-2 Test

Jan 27, 2021  NEW YORK – With recent regulatory approval in Germany, GNA Biosolutions has begun commercializing a rapid, moderate-throughput, sample-to-answer molecular diagnostics instrument called Octea along with an assay for SARS-CoV-2. The Munich-based firm also is using support from the Innovative Medicines Initiative (IMI) to develop its technology into a disposable molecular diagnostics system, which it expects to be a pioneer in instrument-free home-use molecular testing.    GNA Biosolutions received Emergency Use Authorization from the German Federal Institute for Drugs and Medical Devices for its SARS-CoV-2 test on the Octea instrument late last year. The Octea tests eight samples simultaneously, while...

READ MORE
NIH Awards Ceres Nanosciences $8.2M for Wastewater-Based COVID-19 Surveillance

Apr 21, 2021 GenomeWeb NEW YORK – Ceres Nanosciences announced on Wednesday it has been awarded an $8.2 million contract from the National Institutes of Health’s Rapid Acceleration of Diagnostics Initiative. The funding will support the development and implementation of wastewater-based surveillance systems for COVID-19. Manassas, Virginia-based Ceres plans to develop surveillance systems using its Nanotrap particle technology at a network of sites, with an emphasis on underserved and vulnerable populations. In a statement, Ceres noted that wastewater surveillance can be used to monitor trends in SARS-CoV-2 infection at a population level, but that “widespread implementation has been stymied by...

READ MORE
Ceres Nanosciences adding manufacturing facility, 50 jobs to improve COVID-19 tests – Washington Business Journal

By Sara Gilgore  –  Staff Reporter, Washington Business Journal Mar 3, 2021 Updated 20 minutes ago Ceres Nanosciences Inc., a Manassas company working to improve diagnostic testing for the coronavirus, is expanding its footprint with a new manufacturing facility that more than doubles its capacity as it rides a wave of momentum made possible by the pandemic. The local firm, a 12-year-old George Mason University spinout, has taken over 12,000 square feet at Innovation Park in Prince William County, where it also maintains its headquarters. The manufacturing plant delivered in fewer than four months to both support the production its customers currently demand and accommodate...

READ MORE
Ceres Nanosciences Opens Advanced Particle Manufacturing Plant in Northern Virginia to Expand Nanotrap® Particle Manufacturing Capacity for COVID-19 Testing

MANASSAS, Va. — February 17, 2021 — Ceres Nanosciences, a privately held company that makes innovative products to improve diagnostic testing, announced that it has completed the build-out of a new 12,000-square-foot Advanced Particle Manufacturing Plant in Innovation Park, Prince William County, Virginia.  The new facility will be capable of generating a supply of Ceres’ Nanotrap® Magnetic Virus Particles to enable more than 10 million COVID-19 tests per month, with room for added capacity in the future.  Nanotrap® Magnetic Virus Particles improve diagnostic testing for COVID-19 by eliminating the need for RNA extraction kits, reducing sample processing time, and improving the sensitivity of the downstream assays in...

READ MORE
Ceres Nanosciences Nabs $243K SBIR Grant to Adapt SNA Capture Tech for Portable Sequencing

Sep 28, 2020 – GenomeWeb NEW YORK – Ceres Nanosciences announced Monday it has won a $243,000 Phase I Small Business Innovation Research grant from the US Centers for Disease Control and Prevention. The Manassas, Virginia-based infectious disease testing firm will use the funding to adapt its Nanotrap virus particles to work with portable sequencing tools. These hydrogel nanoparticles house chemical affinity baits, providing an alternative to RNA extraction kits and could be used to build viral pathogen surveillance workflows. “We can increase the amount of genomic material that goes into the sequencers by 10-fold,” Ben Lepene, Ceres CTO, said...

READ MORE
1 2 3 5
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER